User:Mattsnod/sandbox

Tislelizumab (BGB-A317) is a humanized monoclonal antibody directed against PD-1. It prevents PD-1 from binding to the ligands PD-L1 and PD-L2 (hence it is a checkpoint inhibitor). It is being investigated as a treatment for advanced solid tumors.

It is designed to bind less to Fc gamma receptors.

It is being developed by BeiGene.

Medical Uses
Tislelizumab was approved by the China National Medical Products Administration on December 27, 2019 to treat patients with classical Hodgkin’s lymphoma (cHL) who have received at least two prior therapies and on April 10, 2020 to treat patients with locally advanced or metastatic urothelial carcinoma (UC) with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Clinical trials
Clinical trials of tislelizumab include:


 * Phase 1 trial in patients with advanced solid tumors (NCT02407990)
 * Phase 3 trial comparing tislelizumab with docetaxel in the second- or third-line setting in patients with non-small cell lung cancer (NSCLC) (NCT03358875)
 * Phase 3 trial comparing tislelizumab with sorafenib as first-line treatment for patients with hepatocellular carcinoma (HCC) (NCT03412773)
 * Phase 2 trial in patients with previously treated unresectable HCC (NCT03419897)
 * Phase 3 trial comparing tislelizumab with chemotherapy as second-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC) (NCT03430843)
 * Phase 3 trial of tislelizumab in combination with chemotherapy versus chemotherapy as first-line treatment for patients with advanced squamous NSCLC (NCT03594747)
 * Phase 3 trial of tislelizumab in combination with chemotherapy versus chemotherapy as first-line treatment for patients with advanced non-squamous NSCLC (NCT03663205)
 * Phase 2 trial in patients with MSI-H/dMMR solid tumors (NCT03736889)
 * Phase 3 trial of tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment for patients with gastric cancer (NCT03777657)
 * Phase 3 trial of tislelizumab in combination with chemotherapy as first-line treatment for patients with ESCC (NCT03783442)
 * Phase 3 trial of tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment in patients with nasopharyngeal cancer (NCT03924986)
 * Phase 3 trial of tislelizumab versus placebo in combination with chemoradiotherapy in patients with localized ESCC (NCT03957590)
 * Phase 3 trial in patients with locally advanced or metastatic urothelial carcinoma (NCT03967977)
 * Phase 2 trial in patients with locally advanced or metastatic urothelial bladder cancer (NCT04004221)
 * Phase 3 trial of tislelizumab combined with platinum and etoposide versus placebo combined with platinum and etoposide in patients with extensive-stage small cell lung cancer (NCT04005716)

Pharmacokinetics
Early phase I clinical trial results give an elimination half-life of 11 to 17 days.